IL300145A - A combination of a BCL-2 inhibitor and a hypomethylating agent for the treatment of cancer, its uses and pharmaceutical preparations - Google Patents

A combination of a BCL-2 inhibitor and a hypomethylating agent for the treatment of cancer, its uses and pharmaceutical preparations

Info

Publication number
IL300145A
IL300145A IL300145A IL30014523A IL300145A IL 300145 A IL300145 A IL 300145A IL 300145 A IL300145 A IL 300145A IL 30014523 A IL30014523 A IL 30014523A IL 300145 A IL300145 A IL 300145A
Authority
IL
Israel
Prior art keywords
day
compound
combination
administered
azacitidine
Prior art date
Application number
IL300145A
Other languages
English (en)
Hebrew (he)
Original Assignee
Servier Lab
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Novartis Ag filed Critical Servier Lab
Publication of IL300145A publication Critical patent/IL300145A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL300145A 2020-07-31 2021-07-30 A combination of a BCL-2 inhibitor and a hypomethylating agent for the treatment of cancer, its uses and pharmaceutical preparations IL300145A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063059419P 2020-07-31 2020-07-31
EP20195633 2020-09-11
PCT/EP2021/071368 WO2022023514A1 (en) 2020-07-31 2021-07-30 Combination of a bcl-2 inhibitor and a hypomethylating agent for treating cancers, uses and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
IL300145A true IL300145A (en) 2023-03-01

Family

ID=77595496

Family Applications (1)

Application Number Title Priority Date Filing Date
IL300145A IL300145A (en) 2020-07-31 2021-07-30 A combination of a BCL-2 inhibitor and a hypomethylating agent for the treatment of cancer, its uses and pharmaceutical preparations

Country Status (15)

Country Link
US (1) US20230270748A1 (https=)
EP (1) EP4188387A1 (https=)
JP (1) JP2023537290A (https=)
KR (1) KR20230044452A (https=)
CN (1) CN116390735A (https=)
AU (1) AU2021316674A1 (https=)
BR (1) BR112023001307A2 (https=)
CA (1) CA3190276A1 (https=)
CL (1) CL2023000242A1 (https=)
CR (1) CR20230046A (https=)
IL (1) IL300145A (https=)
JO (1) JOP20230013A1 (https=)
MX (1) MX2023001335A (https=)
PH (1) PH12023550205A1 (https=)
WO (1) WO2022023514A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025252168A1 (zh) * 2024-06-06 2025-12-11 苏州亚盛药业有限公司 一种含有Bcl-2/Bcl-xL抑制剂的药物组合及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3008975A1 (fr) 2013-07-23 2015-01-30 Servier Lab Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2017300738A1 (en) * 2016-07-22 2019-02-07 Les Laboratoires Servier Combination of a BCL-2 inhibitor and a MCL-1 inhibitor, uses and pharmaceutical compositions thereof
UY38431A (es) 2018-10-31 2020-05-29 Servier Lab Formulación basada en ciclodextrina de un inhibidor de bcl-2
SI3873894T1 (sl) 2018-10-31 2023-08-31 Les Laboratoires Servier Nova sol Bcl-2 inhibitorja, z njo povezana kristalna oblika, postopek za pripravo le-teh in farmacevtski sestavki, ki jih vsebujejo

Also Published As

Publication number Publication date
CA3190276A1 (en) 2022-02-03
KR20230044452A (ko) 2023-04-04
CN116390735A (zh) 2023-07-04
CR20230046A (es) 2023-04-11
WO2022023514A1 (en) 2022-02-03
MX2023001335A (es) 2023-04-27
BR112023001307A2 (pt) 2023-02-14
US20230270748A1 (en) 2023-08-31
CL2023000242A1 (es) 2023-11-10
PH12023550205A1 (en) 2024-06-24
EP4188387A1 (en) 2023-06-07
JP2023537290A (ja) 2023-08-31
JOP20230013A1 (ar) 2023-01-18
AU2021316674A1 (en) 2023-03-02

Similar Documents

Publication Publication Date Title
WO2018015526A1 (en) Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof
US10576050B2 (en) Methods and compositions for treatment of cancer
IL300145A (en) A combination of a BCL-2 inhibitor and a hypomethylating agent for the treatment of cancer, its uses and pharmaceutical preparations
KR20150090091A (ko) 볼라세르티브와의 병용 요법
TWI849001B (zh) Mcl-1抑制劑及米哚妥林(midostaurin)之組合，其用途及醫藥組合物
TWI753178B (zh) Mcl-1抑制劑與血液癌症標準療法之組合，其用途及醫藥組合物
EP3487499A1 (en) Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof
JP2023512724A (ja) リンパ腫の治療におけるピリド［１，２－ａ］ピリミジノン化合物の使用
EP3565547B1 (en) Combination of a mcl-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof
OA21163A (en) Combination of a BCL-2 inhibitor and a hypomethylating agent for treating cancers, uses and pharmaceutical compositions thereof.
HK40092504A (zh) 治疗癌症的bcl-2抑制剂和低甲基化剂的组合、其用途和药物组合物
RU2792057C2 (ru) Комбинация ингибитора mcl-1 и стандартного лекарственного препарата для лечения гематологических злокачественных новообразований, её применение и содержащие её фармацевтические композиции
TW202329968A (zh) 包含mdm2抑制劑、bcl2抑制劑和低甲基化劑的藥物組合及其用於治療血液惡性腫瘤之用途
CN119868392A (zh) 一种内磺酰胺化合物的药物组合
CN118593502A (zh) 一种预防或治疗tp53突变双打击淋巴瘤的联合用药物组合物及其应用
CN119486741A (zh) 1,3,5-三嗪衍生物的药物组合
HK40025641B (zh) Mcl-1抑制剂与用於血液癌症的标准治疗的组合，其用途和药物组合物
HK40025641A (en) Combination of a mcl-1 inhibitor and a standard of care treatment for hematologic cancers, uses and pharmaceutical compositions thereof
NZ789582A (en) Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof
WO2017013271A1 (en) Combination of an inhibitor of phosphatidylinositol 3-kinase delta and a bcl-2 inhibitor, uses and pharmaceutical compositions thereof
EA040162B1 (ru) Комбинация mcl-1 ингибитора и таксанового соединения, их применения и фармацевтические композиции